Long-term follow-up therapy for HCL
| Therapy/reference (year) . | Median patient follow-up, y . | No. of patients . | CR, percentage . | Outcome . |
|---|---|---|---|---|
| Pentostatin | ||||
| Maloisel et al8 (2003) | 5.3 | 238 | 79 | Estimated DFS at 10 y 68.8% |
| Flinn et al17 (2000) | 9.3 | 241 | 76 | Estimated RFS at 10 y 67% |
| Else et al18 (2009) | 14 | 188 | 82 | Relapse at 15 y 47% |
| Cladribine | ||||
| Else et al18 (2009) | 9 | 45 | 76 | Relapse 48% at 15 y |
| Goodman et al19 (2003) | 9 | 207 | 95 | Relapse rate 37% |
| Chadha et al15 (2005) | 9.7 | 86 | 79 | Relapse rate 36% |
| Therapy/reference (year) . | Median patient follow-up, y . | No. of patients . | CR, percentage . | Outcome . |
|---|---|---|---|---|
| Pentostatin | ||||
| Maloisel et al8 (2003) | 5.3 | 238 | 79 | Estimated DFS at 10 y 68.8% |
| Flinn et al17 (2000) | 9.3 | 241 | 76 | Estimated RFS at 10 y 67% |
| Else et al18 (2009) | 14 | 188 | 82 | Relapse at 15 y 47% |
| Cladribine | ||||
| Else et al18 (2009) | 9 | 45 | 76 | Relapse 48% at 15 y |
| Goodman et al19 (2003) | 9 | 207 | 95 | Relapse rate 37% |
| Chadha et al15 (2005) | 9.7 | 86 | 79 | Relapse rate 36% |
DFS indicates disease-free survival (time from date of response until relapse, death, or last observation); and RFS, relapse-free survival (time from date of complete response until either first relapse or death from any cause).